TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy
From MaRDI portal
Publication:6628336
DOI10.1002/SIM.9337zbMATH Open1547.62568MaRDI QIDQ6628336
Daniel Zhiyun Li, Ying Yuan, Li Wang, Young Jack Lee, Ruitao Lin, Yanhong Zhou, Ruobing Li
Publication date: 29 October 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- The Calculation of Posterior Distributions by Data Augmentation
- A utility‐based design for randomized comparative trials with ordinal outcomes and prognostic subgroups
- Statistical Analysis with Missing Data, Third Edition
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
- Bayesian optimal interval designs for phase I clinical trials
Related Items (2)
TITE-gBOIN-ET: time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes ⋮ Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
This page was built for publication: TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6628336)
